Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05370300 · ClinicalTrials.gov registry record
SNAPS Breast Cancer Patient Study Breast Cancer Patients
A clinical trial, sponsored by Immunis.AI.
- Not yet
- Registry status
- 500
- Enrollment target
NCT05370300 is a clinical trial that has not yet begun recruiting, run by Immunis.AI. The registered enrollment target is 500 participants.
The verdict
NCT05370300 has not yet begun recruiting, sponsored by Immunis.AI.
- NOT YET RECRUITING
- Registry status
- 500 participants
- Enrollment target
Study Summary
Differential immunogenomic signatures from peripheral blood CD14 (phagocytic) and CD2 (non-phagocytic) cells have been associated with multiple cancers and disease states. In particular several large clinical studies at Immunis.AI have demonstrated robust immunogenomic signatures in early-stage prostate cancer. Immunis.AI therefore hypothesizes that a peripheral blood immunogenomic signature will identify patients with various stages of breast cancer from healthy negative controls.
Interventions
- DIAGNOSTIC_TEST Blood test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2025-09-01 |
| Est. Completion | 2027-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05370300
The ClinicalTrials.gov registry entry for NCT05370300 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immunis.AI, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood test is the first listed.
NCT05370300 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05370300 about?
NCT05370300 is a clinical study titled "SNAPS Breast Cancer Patient Study Breast Cancer Patients". Differential immunogenomic signatures from peripheral blood CD14 (phagocytic) and CD2 (non-phagocytic) cells have been associated with multiple cancers and disease states. In particular several large clinical studies at Immunis.AI have demonstrated robust immunogenomic signatures in early-stage pros...
What is the current status of trial NCT05370300?
This trial is currently not yet recruiting. The enrollment target is 500 participants. The study started on 2025-09-01. Estimated completion is 2027-12-31.
What interventions are being tested in trial NCT05370300?
The interventions under investigation include: Blood test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05370300?
This trial is sponsored by Immunis.AI, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.